MedTrace Logo

A Study to Evaluate CM336 in Adults With Autoimmune Bullous Disease

NCT06900010 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-06

No results posted yet for this study

Summary

to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Moderate to Severe Autoimmune Bullous Disease

Conditions

  • Autoimmune Bullous Disease

Interventions

BIOLOGICAL

CM336 Injection

subcutaneous CM336 administration

Sponsors & Collaborators

  • Shandong First Medical University

    lead OTHER

Principal Investigators

  • Furen Zhang · Dermatology Hospital affiliated to Shandong First Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-22
Primary Completion
2027-01-01
Completion
2028-01-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06900010 on ClinicalTrials.gov